Axon Enterprise, Inc $AXON Holdings Decreased by Swiss National Bank

Swiss National Bank trimmed its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 3.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 213,200 shares of the biotechnology company’s stock after selling 7,100 shares during the period. Swiss National Bank owned approximately 0.27% of Axon Enterprise worth $153,001,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of AXON. Vanguard Group Inc. boosted its position in Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after acquiring an additional 376,904 shares during the period. Geode Capital Management LLC increased its holdings in shares of Axon Enterprise by 5.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock valued at $1,713,332,000 after purchasing an additional 115,349 shares during the period. Jennison Associates LLC increased its holdings in shares of Axon Enterprise by 53.8% in the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after purchasing an additional 330,213 shares during the period. Vestor Capital LLC lifted its position in shares of Axon Enterprise by 438,636.3% in the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock worth $690,170,000 after purchasing an additional 833,409 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Axon Enterprise in the second quarter worth approximately $637,806,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Axon Enterprise

In related news, CAO Jennifer H. Mak sold 1,500 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the sale, the chief accounting officer directly owned 12,240 shares in the company, valued at approximately $7,019,028. This represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Brittany Bagley sold 2,000 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total transaction of $1,160,000.00. Following the completion of the sale, the chief financial officer owned 103,501 shares of the company’s stock, valued at $60,030,580. This represents a 1.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 26,634 shares of company stock worth $14,963,095. Company insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AXON. UBS Group lowered their price objective on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Royal Bank Of Canada lowered their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $820.00 price target on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Trading Down 2.6%

Shares of NASDAQ AXON opened at $559.06 on Tuesday. The business has a 50 day simple moving average of $535.65 and a 200 day simple moving average of $615.42. Axon Enterprise, Inc has a 52 week low of $396.41 and a 52 week high of $885.91. The stock has a market cap of $44.95 billion, a price-to-earnings ratio of 367.81, a PEG ratio of 12.25 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.55. The firm had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.08 earnings per share. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.